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abnormality that has been associated with resistance to
treatment and shorter survival in MM. We describe the
impact of autologous transplantation (auto) on survival
after treatment with novel agent based induction
regimens.
Methods: We identiﬁed 135 newly diagnosed symptomatic
MM patients who had FISH performed on pre-treatment
bone marrow specimens at our institution between 1/2009
and 12/2012. Standard karyotype and FISH were performed
as previously described (Gerritsen et al. Blood 1992), and
the copy number and percentage of cells involved was
collected. Progression free survival (PFS) and overall survivalFigure 3.(OS) were calculated based on IMWG criteria from diagnosis
and transplant and estimated by Kaplan-Meier A log-rank
test was used to compare survival based on +1q, and Cox
proportional-hazards regression was used to further adjust
for standard MM risk factors.
Results: 25/135 (19%) had +1q. Median age was 60 with the
majority of patients being male (76% in with+1q vs 57%
without, p¼0.112) and Caucasian (76 vs 73%). Median
follow-up was 3.2 years (yrs) (range 0.13-5.5). When
compared to patients without +1q, 40 vs 49% had Interna-
tional Staging System (ISS) Stage I disease, while 28 vs 25%
had Stage II, and 32 vs 26% had Stage III (p¼0.63). Complex
karyotype was seen in 52% with +1q vs 15% without
(p¼0.002). 64 vs 43% (p¼0.075) had extramedullary disease
and 96 vs 78% (p¼0.045) had lytic lesions at diagnosis. Copy
number of +1q ranged from 3-5 with a median of 17% of
cells involved (range 2-98%). Induction regimens included
combination lenalidomide(R), bortezomib (V), cyclophos-
phamide (C), & dexamethasone (D), with 31% receiving RD,
12% VD, 30% RVD, and 16% VCD. Best response to induction
was >very good partial response in 40 vs 54% (p¼0.27). 80
vs 68% underwent auto, and 32 vs 5% both auto and allo.
Median PFS was 2.13 years (1.71- not reached (NR)) with
+1q vs 3.87 years (3.21- NR) without (Figure 1), while
median OS was 4.4 years (2.93-NR) with +1q and was not
reached in those without (Figure 2). After an auto, median
PFS and OS were lower with +1q (p¼0.006, p¼0.006)
(Figure 3). On univariate and multivariate analysis, +1q
and ISS stage were signiﬁcantly associated with worse PFS.
For OS, both ISS and +1q were signiﬁcant on univariate,
but only ISS on multivariate analysis.
Conclusion: Patients were more likely to have complex
karyotypes and lytic lesions at diagnosis. Response to novel
agent induction regimens was high and similar in both
groups. Overall, gain of 1q portends worse PFS and OS which
is not negated by auto transplant.
269
The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell
Lymphoma
Christina A.M. Smith 1, Tracey L. Churay 1, Holly A. Justman 1,
Jessica K. Yu 2, Attaphol Pawarode 1, David Hanauer 3,
John Magenau 1, Steven C. Goldstein 4, Mary Mansour Riwes 5,
Brian Parkin 3, John Levine 2, Daniel R. Couriel 1. 1 Adult
Blood and Marrow Transplant Program, University of
Michigan, Ann Arbor, MI; 2 Pediatric Blood and Marrow
Transplant Program, University of Michigan, Ann Arbor, MI;
3 University of Michigan, Ann Arbor, MI; 4 Hematology/
Oncology, University of Pennsylvania, Philadelphia, PA;
5 Hematology/Oncology, University of Michigan, Ann
Arbor, MI
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the
most frequent lymphoma in the adult population, repre-
senting 25-35% of new non-Hodgkin lymphoma cases each
year (Cultrera & Dalia, 2012). Autologous hematopoietic
stem cell transplant (HSCT) is the standard of care after
relapse following conventional treatment, with a curative
potential of 25-50%, but recurrences are common. Alloge-
neic HSCT represents a salvage option through the beneﬁt
of graft-versus-lymphoma effect. The role of allogeneic
HSCT in patients with advanced DLBCL still remains to be
deﬁned. In this analysis we evaluated the outcomes of
allogeneic HSCT in a group of patients with advanced, high
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mortality.
Methods: The data was obtained through the University of
Michigan Blood and Marrow Transplant Program database,
under an IRB-approved protocol. Demographics, risk factors,
and outcomes were evaluated for all patients with DLBCL
who received an allogeneic transplant between 1996 and
2013.
Results: A total of 112 patients were transplanted between
1996 and 2013. Of these, 33% (n¼37) transformed from
follicular type, 30% (n¼31) had an extranodal component,
and 36% (n¼40) had bone marrow involvement. Twenty-
three (20.5%) patients had a prior autologous transplant.
Overall survival was 46% (95% CI of 36-54%) at 1 year and 26%
(95% CI 17-34%) at ﬁve years; the cumulative incidence of
NRM at one year was 33% (95% CI 25-47%). A high Karnofsky
performance status (KPS) (80%) was the strongest factor
associated with a lower non-relapse mortality (NRM)
(HR¼0.47, p¼0.03). Age, stage of the disease, B-symptoms,
CD34 dose, stem cell source, human leukocyte antigen (HLA)
matching, and conditioning regimen were not signiﬁcantly
associated with NRM. The cumulative incidence of relapse
was 44% (95% CI 35-55%) at one year and 53% (95%CI 42-66%)
at ﬁve years. The cumulative incidence of relapse in patients
without chronic graft-versus-host disease (cGVHD) was
substantially higher than in patients with cGVHD (80% vs.
41%, HR¼2.2, p¼0.1). Relapse accounted for 47% (n¼41) of
the deaths, and the rest (n¼46, 53%) were due to non-relapse
causes. Of these, 39% (n¼18) were due to GVHD-related
causes.
Conclusions: Allogeneic HSCT is a treatment option
for advanced, high risk DLBCL, particularly for patients
with a good performance status, where overall survival
is signiﬁcantly better. Although all-cause mortality and
disease recurrence continue to be high, 26% of thepatients are long-term survivors. In this cohort, cGVHD
was associated with a lower relapse rate, underscoring the
beneﬁts and importance of the graft-versus-lymphoma
effect.270
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Although novel agents improved the outcome of patients
with multiple myeloma (MM), only bortezomib (Bor) is
available for newly diagnosed patients in Japan. We have
started induction therapy with bortezomib-cyclophospha-
mide-dexamethasone (BCD) for newly diagnosed MM
(NDMM) patients since Nov. 2011. Here we report the ef-
ﬁcacy and the feasibility of this induction therapy for
transplant eligible NDMM. Twenty-nine patients received
BCD as induction therapy between Nov. 2011 and Nov.
2013 in our institute. BCD is composed of CPA 300mg/m2
po, Bor 1.3mg/m2 iv or sc, and Dex 40mg/body po on day 1,
8, 15, and 22 with 28 days cycle. Median age was 55 (range
31-67), M/F 18/11, IgG/IgA/IgE/BJ 13/7/1/8, and ISS I/II/III
14/10/5. Eight out of 29 had t(11;14) and 2 had t(4;14).
Median cycles of BCD were 4 (range 2-6), except for one
patient who progressed during ﬁrst cycle. Grade 4 neu-
tropenia (<500/mL) was observed in 2 patients and no
grade 2 thrombocytopenia (<75K/mL) was observed. Grade
3 non-hematologic adverse event was observed in one
patient with varicella-zoster virus reactivation. Response
after BCD was sCR 6, CR 0, VGPR 9, PR 6, MR 3, SD 3, PD 2
(PR 72%, VGPR 52%, and sCR 21%). Two years progres-
sion free survival (PFS) was 78.3% (95% CI: 54.7-90.6).
Autologous stem cell harvest was performed in 27 patients.
Seventeen of 27 patients received high dose melphalan
and ASCT immediately (“upfront” group), while the other
10 patients were scheduled for no ASCT until PD (“late”
group). Maximal response was PR 94%, VGPR 76%, CR
65%, and sCR 59% in “upfront” group, and PR 90%, VGPR
60%, CR 50%, and sCR 40% in “late” group. Two and one
patients have been diagnosed as PD in “upfront” group and
“late” group, respectively. Two years PFS in “upfront”
group was 82.1% (95%CI: 44.4-95.3). Although follow up
period is still short, there was no difference in OS and PFS
between two groups. Our data suggest the efﬁcacy and the
feasibility of BCD for transplant eligible NDMM, but longer
follow up is needed.
